CTLA4 and hepatocellular carcinoma: The increasing use of immune checkpoint inhibitors in HCC has highlighted the importance of immunohistochemical evaluation of PD-L1 and CTLA-4 as a crucial component in both prognostic assessment and therapeutic stratification.